{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-26-000105","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2026-09-29T11:33:10+00:00","discovered_at":"2026-09-29T11:35:00.346040+00:00","generated_at":"2026-10-12T13:42:05.619562+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cartesian's Descartes-08 retreatment cuts MG-ADL 6.6 points at Month 12; no new safety signals; Phase 3 AURORA data 1Q27","bullets":["In 5 retreated MG patients, mean MG-ADL fell 6.6 (±4.2) points and MGC fell 15 (±6.2) points from baseline at Month 12 after retreatment.","Median time from initial treatment completion to first retreatment was 16.6 months; all patients had clinically meaningful MGC (≥3) and MG-ADL (≥2) reductions.","No serious adverse events during retreatment; no cases of CRS, ICANS, cytopenias, or hypogammaglobulinemia; adverse events were transient and mild.","Phase 3 AURORA topline data expected 1Q27; BLA filing in MG expected mid-2027; Descartes-08 has RMAT and Orphan Drug designations and FDA SPA agreement.","Patients had mean disease duration of 13 years and extensive prior treatment histories."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-26-000105","json":"https://secwatch.observer/filing/0001453687-26-000105.json","markdown":"https://secwatch.observer/filing/0001453687-26-000105.md","text":"https://secwatch.observer/filing/0001453687-26-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/0001453687-26-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/rnac-20260929.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:42:05.619562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}